These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 23055947)

  • 1. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma.
    Babu R; Adamson DC
    Core Evid; 2012; 7():93-103. PubMed ID: 23055947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme.
    Del Vecchio CA; Wong AJ
    Curr Opin Mol Ther; 2010 Dec; 12(6):741-54. PubMed ID: 21154166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.
    Schuster J; Lai RK; Recht LD; Reardon DA; Paleologos NA; Groves MD; Mrugala MM; Jensen R; Baehring JM; Sloan A; Archer GE; Bigner DD; Cruickshank S; Green JA; Keler T; Davis TA; Heimberger AB; Sampson JH
    Neuro Oncol; 2015 Jun; 17(6):854-61. PubMed ID: 25586468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rindopepimut: anti-EGFRvIII peptide vaccine, oncolytic.
    Gedeon PC; Choi BD; Sampson JH; Bigner DD
    Drugs Future; 2013 Mar; 38(3):147-155. PubMed ID: 25663738
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme.
    Swartz AM; Li QJ; Sampson JH
    Immunotherapy; 2014; 6(6):679-90. PubMed ID: 25186601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
    Weller M; Butowski N; Tran DD; Recht LD; Lim M; Hirte H; Ashby L; Mechtler L; Goldlust SA; Iwamoto F; Drappatz J; O'Rourke DM; Wong M; Hamilton MG; Finocchiaro G; Perry J; Wick W; Green J; He Y; Turner CD; Yellin MJ; Keler T; Davis TA; Stupp R; Sampson JH;
    Lancet Oncol; 2017 Oct; 18(10):1373-1385. PubMed ID: 28844499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The EGFR variant III mutant as a target for immunotherapy of glioblastoma multiforme.
    Chistiakov DA; Chekhonin IV; Chekhonin VP
    Eur J Pharmacol; 2017 Sep; 810():70-82. PubMed ID: 28583430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ReACT Phase II trial: a critical evaluation of the use of rindopepimut plus bevacizumab to treat EGFRvIII-positive recurrent glioblastoma.
    Gatson NT; Weathers SP; de Groot JF
    CNS Oncol; 2016; 5(1):11-26. PubMed ID: 26670466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospect of rindopepimut in the treatment of glioblastoma.
    Elsamadicy AA; Chongsathidkiet P; Desai R; Woroniecka K; Farber SH; Fecci PE; Sampson JH
    Expert Opin Biol Ther; 2017 Apr; 17(4):507-513. PubMed ID: 28274144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial.
    Reardon DA; Desjardins A; Vredenburgh JJ; O'Rourke DM; Tran DD; Fink KL; Nabors LB; Li G; Bota DA; Lukas RV; Ashby LS; Duic JP; Mrugala MM; Cruickshank S; Vitale L; He Y; Green JA; Yellin MJ; Turner CD; Keler T; Davis TA; Sampson JH;
    Clin Cancer Res; 2020 Apr; 26(7):1586-1594. PubMed ID: 32034072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas.
    Del Vecchio CA; Li G; Wong AJ
    Expert Rev Vaccines; 2012 Feb; 11(2):133-44. PubMed ID: 22309662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.
    Sampson JH; Heimberger AB; Archer GE; Aldape KD; Friedman AH; Friedman HS; Gilbert MR; Herndon JE; McLendon RE; Mitchell DA; Reardon DA; Sawaya R; Schmittling RJ; Shi W; Vredenburgh JJ; Bigner DD
    J Clin Oncol; 2010 Nov; 28(31):4722-9. PubMed ID: 20921459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.
    Sampson JH; Aldape KD; Archer GE; Coan A; Desjardins A; Friedman AH; Friedman HS; Gilbert MR; Herndon JE; McLendon RE; Mitchell DA; Reardon DA; Sawaya R; Schmittling R; Shi W; Vredenburgh JJ; Bigner DD; Heimberger AB
    Neuro Oncol; 2011 Mar; 13(3):324-33. PubMed ID: 21149254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients.
    Heimberger AB; Sampson JH
    Expert Opin Biol Ther; 2009 Aug; 9(8):1087-98. PubMed ID: 19591631
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme.
    Sampson JH; Archer GE; Mitchell DA; Heimberger AB; Herndon JE; Lally-Goss D; McGehee-Norman S; Paolino A; Reardon DA; Friedman AH; Friedman HS; Bigner DD
    Mol Cancer Ther; 2009 Oct; 8(10):2773-9. PubMed ID: 19825799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epidermal Growth Factor Receptor-Targeted Neoantigen Peptide Vaccination for the Treatment of Non-Small Cell Lung Cancer and Glioblastoma.
    Li F; Wu H; Du X; Sun Y; Rausseo BN; Talukder A; Katailiha A; Elzohary L; Wang Y; Wang Z; Lizée G
    Vaccines (Basel); 2023 Sep; 11(9):. PubMed ID: 37766136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination epidermal growth factor receptor variant III peptide-pulsed dendritic cell vaccine with miR-326 results in enhanced killing on EGFRvIII-positive cells.
    Li J; Wang F; Wang G; Sun Y; Cai J; Liu X; Zhang J; Lu X; Li Y; Chen M; Chen L; Jiang C
    Oncotarget; 2017 Apr; 8(16):26256-26268. PubMed ID: 28412740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines.
    Schmittling RJ; Archer GE; Mitchell DA; Heimberger A; Pegram C; Herndon JE; Friedman HS; Bigner DD; Sampson JH
    J Immunol Methods; 2008 Nov; 339(1):74-81. PubMed ID: 18775433
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype.
    Choe G; Park JK; Jouben-Steele L; Kremen TJ; Liau LM; Vinters HV; Cloughesy TF; Mischel PS
    Clin Cancer Res; 2002 Sep; 8(9):2894-901. PubMed ID: 12231534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens.
    Feldkamp MM; Lala P; Lau N; Roncari L; Guha A
    Neurosurgery; 1999 Dec; 45(6):1442-53. PubMed ID: 10598712
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.